PMID- 29564734
OWN - NLM
STAT- MEDLINE
DCOM- 20181109
LR  - 20220801
IS  - 1179-2000 (Electronic)
IS  - 1177-1062 (Linking)
VI  - 22
IP  - 3
DP  - 2018 Jun
TI  - Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their 
      Prevention.
PG  - 297-314
LID - 10.1007/s40291-018-0330-3 [doi]
AB  - Adverse drug reactions (ADRs) affect many patients and remain a major public 
      health problem, as they are a common cause of morbidity and mortality. It is 
      estimated that ADRs are responsible for about 6% of hospital admissions and about 
      9% of hospitalization costs. Skin is the organ that is most frequently involved 
      in ADRs. Drug-induced skin injuries vary from mild maculopapular eruptions (MPE) 
      to severe cutaneous adverse reactions (SCARs) that are potentially life 
      threatening. Genetic factors have been suggested to contribute to these SCARs, 
      and most significant genetic associations have been identified in the major 
      histocompatibility complex (MHC) genes. Common drugs associated with SCARs 
      connected with strong genetic risk factors include antiepileptic drugs (AEDs), 
      allopurinol, abacavir, nevirapine, sulfonamides, dapsone, non-steroidal 
      anti-inflammatory drugs (NSAIDs), and analgesic drugs. However, genetic 
      associations vary between different ethnic populations. Differences may in part 
      be explained by the different prevalence of HLA (human leukocyte antigen) alleles 
      among ethnic groups. In this review, we present and discuss the recent advances 
      in genetic associations with ADRs in the skin. Many of these ADRs are now 
      preventable with pharmacogenetic screening.
FAU - Gerogianni, Kalliopi
AU  - Gerogianni K
AD  - Department of Pharmacology, Faculty of Medicine, University of Thessaly, 
      Biopolis, 41500, Larissa, Greece. kalgerog@yahoo.com.
FAU - Tsezou, Aspasia
AU  - Tsezou A
AD  - Laboratory of Cytogenetics and Molecular Genetics, Faculty of Medicine, 
      University of Thessaly, Biopolis, 41500, Larissa, Greece.
AD  - Department of Biology, Faculty of Medicine, University of Thessaly, Biopolis, 
      41500, Larissa, Greece.
FAU - Dimas, Konstantinos
AU  - Dimas K
AUID- ORCID: 0000-0001-7481-9148
AD  - Department of Pharmacology, Faculty of Medicine, University of Thessaly, 
      Biopolis, 41500, Larissa, Greece. kdimas@med.uth.gr.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Mol Diagn Ther
JT  - Molecular diagnosis & therapy
JID - 101264260
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anticonvulsants)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (Gout Suppressants)
RN  - 0 (HLA-B Antigens)
RN  - 33CM23913M (Carbamazepine)
RN  - 63CZ7GJN5I (Allopurinol)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Alleles
MH  - Allopurinol/adverse effects
MH  - Anti-HIV Agents/adverse effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Anticonvulsants/adverse effects
MH  - Carbamazepine/adverse effects
MH  - Dideoxynucleosides/adverse effects
MH  - Drug Hypersensitivity/*genetics/immunology/pathology/prevention & control
MH  - Gene Expression
MH  - *Genetic Testing
MH  - Gout Suppressants/adverse effects
MH  - HLA-B Antigens/*genetics/immunology
MH  - Humans
MH  - *Pharmacogenetics
MH  - Skin/*drug effects/immunology/pathology
EDAT- 2018/03/23 06:00
MHDA- 2018/11/10 06:00
CRDT- 2018/03/23 06:00
PHST- 2018/03/23 06:00 [pubmed]
PHST- 2018/11/10 06:00 [medline]
PHST- 2018/03/23 06:00 [entrez]
AID - 10.1007/s40291-018-0330-3 [pii]
AID - 10.1007/s40291-018-0330-3 [doi]
PST - ppublish
SO  - Mol Diagn Ther. 2018 Jun;22(3):297-314. doi: 10.1007/s40291-018-0330-3.